Science Times Observer: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Times Observer.

Press releases published on September 9, 2026

Sep. 9, 2026

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

Indeterminate GlobeNewswire

Sep. 9, 2026

Solstice Oncology Launches with $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy

Indeterminate GlobeNewswire

Sep. 9, 2026

Troilus Reports Updated Technical Report Following Completion of Basic Engineering, Delivering After-Tax US$3.2 Billion NPV5%, 22% IRR, and Cashflow of US$6.9 Billion at Base Case Gold Price of US $3,600/oz

Indeterminate GlobeNewswire

Sep. 9, 2026

Troilus présente un rapport technique mis à jour à la suite de l’achèvement de l’ingénierie de base, faisant ressortir une VAN après impôt à 5 % de 3,2 G$ US, un TRI de 22 % et des flux de trésorerie de 6,9 G$ US selon le scénario de base reposant sur …

Indeterminate GlobeNewswire

Sep. 9, 2026

Koryx Copper Announces Further Drill Results at the Haib Copper Project in Southern Namibia

Indeterminate GlobeNewswire

Sep. 9, 2026

Nobel Announces Drill Plan for the Cuprita Copper Project and Provides Update on the Janett Project

Indeterminate GlobeNewswire

Sep. 9, 2026

Beeline Medicines Announces Positive Topline Results from Global Phase 2 Study of Afimetoran in Systemic Lupus Erythematosus

Indeterminate GlobeNewswire

Sep. 9, 2026

Xanadu and ASML Announce Collaboration to Advance Lithography for Photonic Quantum Hardware

Indeterminate GlobeNewswire

Sep. 9, 2026

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Indeterminate GlobeNewswire

Sep. 9, 2026

Broncos Country, This One’s for You: Breckenridge Distillery Kicks Off Another Season with the Denver Broncos and a Limited-Edition Whiskey Collection Honoring “The Drive”

Indeterminate GlobeNewswire

Sep. 9, 2026

ABBYY Study Finds Business Leaders Disagree on Who Has Ultimate Responsibility When AI Goes Wrong

Indeterminate GlobeNewswire

Sep. 9, 2026

Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

Indeterminate GlobeNewswire

Sep. 9, 2026

Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib

Indeterminate GlobeNewswire

Sep. 9, 2026

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

Indeterminate GlobeNewswire

Sep. 9, 2026

Erdene Enters Into Automatic Securities Purchase Plan

Indeterminate GlobeNewswire

Sep. 9, 2026

Talisker Reports Mustang Underground Face Sample Results Defining a 79-metre Strike Length High-grade Shoot Averaging 64.8 g/t on the 1030 Level

Indeterminate GlobeNewswire

Sep. 9, 2026

MapLight Therapeutics to Participate in Upcoming Investor Conference

Indeterminate GlobeNewswire

Sep. 9, 2026

ODDITY Tech Reports Second Quarter 2026 Results, Expects Sequential Revenue Improvement in the Third Quarter

Indeterminate GlobeNewswire

Sep. 9, 2026

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

Indeterminate GlobeNewswire

Sep. 9, 2026

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Indeterminate GlobeNewswire